Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025344 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KDM4EHPGDNPC1 | |
| SCHEMBL4124819 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KDM4EHPGDNPC1 | |
| Hydrochloric Acid SCHEMBL400411 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1KDM4EHPGDNPC1 | |
| SCHEMBL25977938 | 0.84 | CNR1 (0.44) | SMN1; SMN2ALDH1A1KDM4EHPGDTRPV1 | |
| SCHEMBL25977894 | 0.83 | GABRG2 (0.51) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL16099428 | 0.82 | AR (0.62) | SMN1; SMN2MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL9822836 | 0.80 | RAB9A (0.61) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| 2-Phenylquinoline SCHEMBL28311274 | 0.80 | AR (0.59) | SMN1; SMN2MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL22281899 | 0.79 | PARP1 (0.54) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL22970618 | 0.79 | MAPT (0.49) | SMN1; SMN2MAPTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566721-B2 | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566721-B2 | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566721-B2 | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-2051982-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008018881-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018881-A1 | 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | IGF1R, BRCA1, MAP2K6 | SMN1; SMN2 1973/4885MAPT 1585/4885ALDH1A1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.